Cannabis for Endometriosis: How Women Are Using THC and CBD for Menstrual Pain Relief

Endometriosis affects an estimated 190 million women and people with uteruses worldwide — roughly 10% of those of reproductive age. The condition occurs when tissue similar to the uterine lining grows outside the uterus, causing chronic inflammation, adhesions, and pain that can range from debilitating to life-altering.

Standard treatments include hormonal therapies, NSAIDs, and surgery, but many patients report inadequate relief or intolerable side effects. Increasingly, those patients are turning to cannabis. A growing body of research suggests their instinct may be scientifically sound, rooted in the endocannabinoid system’s role in reproductive biology.

The Endocannabinoid System and Reproductive Health

The endocannabinoid system (ECS) is densely expressed in reproductive tissues. Endocannabinoid receptors — both CB1 and CB2 — are found in the uterus, ovaries, fallopian tubes, and endometrial tissue itself. This is not incidental. The ECS plays a documented role in embryo implantation, menstrual cycling, and inflammation regulation within the reproductive tract.

Research published in Human Reproduction Update has established that women with endometriosis show altered endocannabinoid signaling. Specifically, endometriotic tissue has been found to express lower levels of CB1 receptors compared to healthy endometrial tissue. This deficit may contribute to the unchecked cell proliferation and inflammation that characterize the disease.

The implication is straightforward: if the endocannabinoid system is involved in regulating the very processes that go wrong in endometriosis, supplementing that system with phytocannabinoids from cannabis could offer therapeutic benefit.

What the Research Shows

Pain Reduction

A 2023 survey published in BMC Women’s Health found that 76% of women who used cannabis for endometriosis-related pain reported significant improvement. The most commonly used forms were inhaled cannabis (for acute pain episodes) and oral CBD products (for daily management).

A 2024 observational study from the University of Western Sydney tracked 252 women with diagnosed endometriosis who used medicinal cannabis over 12 months. Key findings included:

• Average pain scores decreased from 7.6 to 4.1 on a 10-point scale
• 62% of participants reduced their use of opioid pain medications
• 48% reduced their use of NSAIDs
• Sleep quality improved in 71% of participants

These are observational results, not randomized controlled trials, and that distinction matters. But the consistency of findings across multiple studies and countries is building a case that warrants rigorous clinical investigation.

Anti-Inflammatory Mechanisms

CBD has well-documented anti-inflammatory properties that operate through multiple pathways relevant to endometriosis. It inhibits the release of pro-inflammatory cytokines, modulates the COX-2 enzyme (the same pathway targeted by NSAIDs), and activates TRPV1 receptors involved in pain perception.

THC adds its own anti-inflammatory effects through direct CB1 and CB2 receptor activation, along with analgesic properties that address pain at the central nervous system level.

Research from the Czech Academy of Sciences published in 2025 demonstrated that a combination of THC and CBD reduced the viability of endometriotic cell cultures in vitro — suggesting cannabinoids may have potential not just for symptom management but for slowing disease progression. This remains preclinical and should not be interpreted as a treatment claim, but it has generated significant interest in the gynecological research community.

How Patients Are Using Cannabis

Survey data consistently shows that endometriosis patients use cannabis in specific patterns that differ from recreational use:

For acute pain flares: Inhaled cannabis (vaporized flower or concentrates) is preferred because of rapid onset. Patients report reaching for high-THC products during severe pain episodes, often when rescue medications like prescription NSAIDs or opioids have been insufficient.

For daily management: Oral CBD products — tinctures, capsules, and oils in the 25-75 mg daily range — are the most common approach. Many patients describe using CBD as a baseline anti-inflammatory alongside their conventional treatment plan.

Topical applications: CBD-infused creams and suppositories applied to the pelvic area are gaining popularity, though clinical evidence for transdermal cannabinoid delivery to deep pelvic structures remains limited. Patients report relief from superficial pain and muscle tension in the pelvic floor.

Combination approaches: The most commonly reported strategy is daily oral CBD with inhaled THC reserved for breakthrough pain. This mirrors the “entourage effect” theory, which suggests that multiple cannabinoids working together may be more effective than isolated compounds. For a broader look at cannabis and pain research, see our article on cannabis and skin conditions in dermatology.

What Gynecologists Are Saying

The medical establishment’s response is cautious but evolving. A 2025 survey of OB-GYN physicians published in the Journal of Women’s Health found that 34% had discussed cannabis with endometriosis patients, up from 18% in 2021. However, only 12% felt confident enough in the evidence to actively recommend it.

The primary concerns physicians cite include:

• Lack of randomized controlled trial data
• Variability in product quality and dosing in consumer markets
• Potential interactions with hormonal therapies
• Effects on fertility for patients who may be trying to conceive (THC has been associated with disruptions to ovulation timing in some studies)

Dr. Joanna Stanton, a reproductive endocrinologist at Mount Sinai, captured the prevailing clinical sentiment in a 2025 interview: “I don’t discourage patients from trying CBD for pain management, but I do ask them to be transparent about it so we can monitor for interactions and adjust their care plan accordingly. The data is promising but incomplete.”

Important Considerations

Fertility implications: Women actively trying to conceive should be particularly cautious with THC. Animal studies and limited human data suggest that THC may affect ovulation, implantation, and early embryo development. CBD appears to have a more benign profile in this regard, but data remains sparse.

Drug interactions: Cannabis can interact with hormonal medications, blood thinners, and certain antidepressants commonly prescribed alongside endometriosis treatment. Patients should consult their healthcare provider before adding cannabis to an existing medication regimen.

Product quality: In legal markets, purchasing lab-tested products with verified cannabinoid content is essential for consistent dosing. Unregulated products may contain contaminants or inaccurate potency labels. Our cannabis marketing regulations guide covers how product claims are regulated across states.

Legal access: Medical cannabis programs in many states include chronic pain or intractable pain as qualifying conditions, which endometriosis patients typically meet. Some states have added endometriosis specifically to their qualifying condition lists.

The Path Forward

Multiple clinical trials for cannabis and endometriosis are currently underway. A Phase II trial sponsored by a Canadian research hospital is studying a 1:1 THC-to-CBD oral formulation specifically for endometriosis pain, with results expected in late 2026. An Australian trial is examining CBD-only suppositories for pelvic pain.

Until that data arrives, the picture is one of promising but preliminary evidence, consistent patient-reported benefit, and a medical establishment that is slowly opening the door. For the millions of women living with endometriosis who have found their current options insufficient, cannabis represents a tool worth discussing with their healthcare team — not as a replacement for conventional treatment, but as a potential complement to it.